Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 5/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23175882 | 0.92 | MEN1 (0.63) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL7132152 | 0.87 | MEN1 (0.50) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL15147831 | 0.84 | DNM1 (0.42) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL24477430 | 0.84 | FAAH (0.53) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL13241299 | 0.82 | MEN1 (0.43) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL12934925 | 0.82 | FAAH (0.78) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL5909190 | 0.82 | FAAH (0.71) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL23420467 | 0.81 | FAAH (0.50) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL12934924 | 0.80 | FAAH (0.83) | MEN1FAAHMAPK1KMT2ADNM1 | |
| SCHEMBL12934930 | 0.80 | FAAH (0.83) | MEN1FAAHMAPK1KMT2ADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4241767-A2 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-11351265-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210292303-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9549983-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351265-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | MEN1 1690/4885FAAH 1051/4885MAPK1 3823/4885 |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | MEN1 1690/4885FAAH 1051/4885MAPK1 3823/4885 |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | MEN1 1690/4885FAAH 1051/4885MAPK1 3823/4885 |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | MEN1 1518/4885FAAH 1399/4885MAPK1 4590/4885 |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | MEN1 1518/4885FAAH 1399/4885MAPK1 4590/4885 |
| US-20210292303-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | SGMS2, SLC43A1, SGMS1 | MEN1 1518/4885FAAH 1399/4885MAPK1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.